P181 Secondary cutaneous DLBCL has a higher IPI score and worse prognosis than DLBCL, leg type = P181 Secondary cutaneous DLBCL has a higher IPI score and worse prognosis than DLBCL, leg type

다국어 초록 (Multilingual Abstract)

<div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div>

다국어 초록 (Multilingual Abstract)

Background: Differences in skin lesions and survival data for cutaneous diffuse large B-cell lymphoma (DLBCL) depending on primary tumor site are currently unknown. Objectives: we aimed to analyze the clinical features of skin lesions and survival outcomes of cutaneous DLBCL according to the primary tumor site. Methods: Forty-seven patients with cutaneous DLBCL were classified as primary cutaneous DLBCL or cutaneous DLBCL secondary to primary disease. Clinical features, survival outcomes, and prognostic factors were analyzed using patient medical records. Survival outcomes were analyzed using the Kaplan.Meier method and compared using the log-rank test. Results: Although skin lesion characteristics did not significantly differ between groups, secondary cutaneous DLBCL more commonly presented disseminated skin lesions that involved multiple anatomical sites. Primary cutaneous DLBCL demonstrated a less aggressive clinical course and better survival outcomes than secondary cutaneous DLBCL. Disseminated skin lesions and a location on the leg significantly affected the prognosis of primary cutaneous DLBCL. The multiplicity of skin lesions and time point of cutaneous involvement were associated with prognosis in secondary cutaneous DLBCL. Conclusion: Although the clinical features of skin lesions were similar regardless of subgroup, survival outcomes and prognostic factors differed depending on the primary tumor site of cutaneous DLBCL.